223 related articles for article (PubMed ID: 24111983)
1. Ziprasidone in adolescents with schizophrenia: results from a placebo-controlled efficacy and long-term open-extension study.
Findling RL; Cavuş I; Pappadopulos E; Vanderburg DG; Schwartz JH; Gundapaneni BK; DelBello MP
J Child Adolesc Psychopharmacol; 2013 Oct; 23(8):531-44. PubMed ID: 24111983
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, long-term safety, and tolerability of ziprasidone in children and adolescents with bipolar disorder.
Findling RL; Cavuş I; Pappadopulos E; Vanderburg DG; Schwartz JH; Gundapaneni BK; DelBello MP
J Child Adolesc Psychopharmacol; 2013 Oct; 23(8):545-57. PubMed ID: 24111980
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, Safety, and Tolerability of Flexibly Dosed Ziprasidone in Children and Adolescents with Mania in Bipolar I Disorder: A Randomized Placebo-Controlled Replication Study.
Findling RL; Atkinson S; Bachinsky M; Raiter Y; Abreu P; Ianos C; Chappell P
J Child Adolesc Psychopharmacol; 2022 Apr; 32(3):143-152. PubMed ID: 35394365
[No Abstract] [Full Text] [Related]
4. Safety and Efficacy from an 8 Week Double-Blind Trial and a 26 Week Open-Label Extension of Asenapine in Adolescents with Schizophrenia.
Findling RL; Landbloom RP; Mackle M; Pallozzi W; Braat S; Hundt C; Wamboldt MZ; Mathews M
J Child Adolesc Psychopharmacol; 2015 Jun; 25(5):384-96. PubMed ID: 26091193
[TBL] [Abstract][Full Text] [Related]
5. Tolerability of oral ziprasidone in children and adolescents with bipolar mania, schizophrenia, or schizoaffective disorder.
DelBello MP; Versavel M; Ice K; Keller D; Miceli J
J Child Adolesc Psychopharmacol; 2008 Oct; 18(5):491-9. PubMed ID: 18928413
[TBL] [Abstract][Full Text] [Related]
6. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial.
Addington DE; Pantelis C; Dineen M; Benattia I; Romano SJ
J Clin Psychiatry; 2004 Dec; 65(12):1624-33. PubMed ID: 15641867
[TBL] [Abstract][Full Text] [Related]
8. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial.
Keck PE; Versiani M; Potkin S; West SA; Giller E; Ice K;
Am J Psychiatry; 2003 Apr; 160(4):741-8. PubMed ID: 12668364
[TBL] [Abstract][Full Text] [Related]
9. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.
Cutler AJ; Kalali AH; Weiden PJ; Hamilton J; Wolfgang CD
J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S20-8. PubMed ID: 18334909
[TBL] [Abstract][Full Text] [Related]
10. Ziprasidone and the corrected QT interval: a comprehensive summary of clinical data.
Camm AJ; Karayal ON; Meltzer H; Kolluri S; O'Gorman C; Miceli J; Tensfeldt T; Kane JM
CNS Drugs; 2012 Apr; 26(4):351-65. PubMed ID: 22452529
[TBL] [Abstract][Full Text] [Related]
11. Ziprasidone in treatment-resistant schizophrenia: a 52-week, open-label continuation study.
Loebel AD; Khanna S; Rajadhyaksha S; Siu CO; Giller E; Potkin SG
J Clin Psychiatry; 2007 Sep; 68(9):1333-8. PubMed ID: 17915970
[TBL] [Abstract][Full Text] [Related]
12. Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double- blind, placebo-controlled, multicenter studies.
Keck PE; Reeves KR; Harrigan EP;
J Clin Psychopharmacol; 2001 Feb; 21(1):27-35. PubMed ID: 11199944
[TBL] [Abstract][Full Text] [Related]
13. [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].
Bartkó G; Trixler M; Bitter I; Degrell I; Füredi J; Faludi G;
Neuropsychopharmacol Hung; 2006 Dec; 8(4):201-9. PubMed ID: 17211055
[TBL] [Abstract][Full Text] [Related]
14. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial.
Keck P; Buffenstein A; Ferguson J; Feighner J; Jaffe W; Harrigan EP; Morrissey MR
Psychopharmacology (Berl); 1998 Nov; 140(2):173-84. PubMed ID: 9860108
[TBL] [Abstract][Full Text] [Related]
15. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia.
Findling RL; Robb A; Nyilas M; Forbes RA; Jin N; Ivanova S; Marcus R; McQuade RD; Iwamoto T; Carson WH
Am J Psychiatry; 2008 Nov; 165(11):1432-41. PubMed ID: 18765484
[TBL] [Abstract][Full Text] [Related]
16. Switching from quetiapine to ziprasidone: a sixteen-week, open-label, multicenter study evaluating the effectiveness and safety of ziprasidone in outpatient subjects with schizophrenia or schizoaffective disorder.
Karayal ON; Glue P; Bachinsky M; Stewart M; Chappell P; Kolluri S; Cavus I
J Psychiatr Pract; 2011 Mar; 17(2):100-9. PubMed ID: 21430488
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness, tolerability, and safety of ziprasidone in patients with schizophrenia or schizoaffective disorder: results of a multi-centre observational trial.
Kudla D; Lambert M; Domin S; Kasper S; Naber D
Eur Psychiatry; 2007 Apr; 22(3):195-202. PubMed ID: 17140769
[TBL] [Abstract][Full Text] [Related]
18. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia.
Breier A; Berg PH; Thakore JH; Naber D; Gattaz WF; Cavazzoni P; Walker DJ; Roychowdhury SM; Kane JM
Am J Psychiatry; 2005 Oct; 162(10):1879-87. PubMed ID: 16199834
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of ziprasidone in the treatment of first-episode psychosis: an 8-week, open-label, multicenter trial.
Zhao T; Park TW; Yang JC; Huang GB; Kim MG; Lee KH; Chung YC
Int Clin Psychopharmacol; 2012 Jul; 27(4):184-90. PubMed ID: 22426471
[TBL] [Abstract][Full Text] [Related]
20. A comparison of ziprasidone and risperidone in the long-term treatment of schizophrenia: a 44-week, double-blind, continuation study.
Addington DE; Labelle A; Kulkarni J; Johnson G; Loebel A; Mandel FS
Can J Psychiatry; 2009 Jan; 54(1):46-54. PubMed ID: 19175979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]